Regeneron Pharmaceuticals, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
8
Buy
Overall
6.2
Hold
Quality
Health
Growth
Valuation
Sentiment
REGN
Clean balance sheet with low leverage (0.1× debt-to-equity).
UNH
82% of 28 covering analysts rate it Buy or Strong Buy.
⚠ limited growth momentum.
Analyst Consensus
BUY
Target $877.73 (+24.4%)
28 analysts
BUY
Target $387.27 (+4.9%)
26 analysts
Fundamentals
REGN
UNH
17.2×
Trailing P/E
27.9×
13.4×
Forward P/E
17.8×
29.6%
Profit Margin
2.7%
44.6%
Gross Margin
18.8%
14.5%
ROE
12.2%
19.0%
Revenue Growth
2.0%
-7.2%
Earnings Growth
0.7%
0.40
Beta
0.41
—
Price / Book
—
$74.0B
Market Cap
$335.3B
$476 – $821
52-Week Range
$235 – $412
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.